Comparison
6q Terminal Deletion Syndrome C4304514 vs 2 Hydroxyglutarate Aciduria C5139239
Clinical comparison between 6Q Terminal Deletion Syndrome and 2 Hydroxyglutarate Aciduria for differential diagnosis and treatment planning.
6q Terminal Deletion Syndrome C4304514
A chromosomal disorder involving deletion of genetic material at the end of chromosome 6, leading to developmental delays and variable physical features.
2 Hydroxyglutarate Aciduria C5139239
A metabolic disorder causing buildup of 2-hydroxyglutaric acid. It may affect the brain and nervous system. Management includes supportive therapies and monitoring for complications.
6 comparison axes
Onset
6q Terminal Deletion Syndrome C4304514
0-0
2 Hydroxyglutarate Aciduria C5139239
0-10
Onset patterns differ
Severity
6q Terminal Deletion Syndrome C4304514
severe
2 Hydroxyglutarate Aciduria C5139239
moderate
Different severity levels
Chronic
6q Terminal Deletion Syndrome C4304514
Chronic
2 Hydroxyglutarate Aciduria C5139239
Chronic
Differing course
Communicable
6q Terminal Deletion Syndrome C4304514
No
2 Hydroxyglutarate Aciduria C5139239
No
Different transmission
Body System
6q Terminal Deletion Syndrome C4304514
congenital
2 Hydroxyglutarate Aciduria C5139239
metabolic
Same/different system
Category
6q Terminal Deletion Syndrome C4304514
genetic
2 Hydroxyglutarate Aciduria C5139239
metabolic
Different category
Bottom line
6q-terminal-deletion-syndrome-C4304514 and 2-hydroxyglutarate-aciduria-C5139239 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6q Terminal Deletion Syndrome C4304514 | 2 Hydroxyglutarate Aciduria C5139239 | Discriminating power |
|---|---|---|---|
| Developmental delay | Expected from birth as part of a chromosomal disorder, with variable features. | May appear in childhood if brain or nervous-system involvement develops. | Moderate |
| Physical features | Variable congenital physical differences may be present. | No specific physical pattern is established by the supplied data. | Moderate |
| Metabolic signs | Not described as an acid accumulation disorder. | Defined by buildup of 2-hydroxyglutaric acid, which is a laboratory finding rather than a complete diagnosis by itself. | High |
When to favor each condition
Choose 6q Terminal Deletion Syndrome C4304514 when
Congenital developmental delay with suspected chromosomal cause
The condition is a genetic deletion present from birth.
High
Variable physical features without a described metabolic aciduria
Physical variability fits the chromosomal description better than acid accumulation.
Moderate
Need to distinguish congenital from metabolic etiology
Chromosomal testing addresses the deletion category.
High
Choose 2 Hydroxyglutarate Aciduria C5139239 when
Suspected organic acid accumulation
The defining feature is buildup of 2-hydroxyglutaric acid.
High
Childhood neurologic concerns with possible metabolic disease
Onset may extend through early childhood and the nervous system may be affected.
Moderate
Need for metabolic monitoring rather than chromosomal confirmation
Management is described as supportive care and complication monitoring.
Moderate
How key tests differ
| Test | 6q Terminal Deletion Syndrome C4304514 | 2 Hydroxyglutarate Aciduria C5139239 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify terminal chromosome 6 deletion; exact method and result require specialist review. | Not expected to establish this metabolic condition. | A chromosomal result supports the left category but does not exclude unrelated metabolic disease. |
| Urine organic acid analysis | No characteristic aciduria is established here. | May show elevated 2-hydroxyglutaric acid; no cutoff is supplied. | An abnormal metabolite result needs clinical and genetic correlation before diagnosis. |
| Neurologic assessment | May document developmental delay and associated features. | May document brain or nervous-system effects when present. | Findings overlap and are not independently diagnostic. |
Prognosis comparison
6q Terminal Deletion Syndrome C4304514
- Outcome
- Often severe and lifelong, but individual outcome is variable and not quantified here.
- Factors
- Extent of deletion, developmental findings, and associated features may influence course.
2 Hydroxyglutarate Aciduria C5139239
- Outcome
- Described as moderate overall, with possible neurologic effects and variable course.
- Factors
- Degree of metabolite accumulation, neurologic involvement, and response to supportive care may matter.
Time frame: Both are chronic; left begins at birth, while right may present from birth through about age 10.
Prognosis cannot be individualized from these sparse data and needs specialist interpretation.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurodevelopmental impairment | Developmental delay is a core described consequence. Brain and nervous-system involvement may occur. Severity and specific deficits are variable and not fully established. |
| Associated congenital differences | Variable physical features may occur. Not established from the supplied description. Do not infer a particular malformation pattern. |
| Metabolic complications | Not described. Monitoring for complications is advised, but specific complications are not listed. Avoid assuming crises, organ failure, or mortality. |
Patient education highlights
- HighDifferent causes
One is a chromosomal deletion; the other involves accumulation of a metabolite. Neither is communicable.
- HighTesting limits
An abnormal test supports evaluation but should be interpreted by a clinician with the full history.
- MediumCare approach
Both are chronic. Supportive care and monitoring are appropriate; no treatment dose is established here.